| Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas … J Arca-Suárez, C Lasarte-Monterrubio, BK Rodiño-Janeiro, G Cabot, ... Journal of Antimicrobial Chemotherapy 76 (1), 91-100, 2021 | 39 | 2021 |
| Activity of imipenem/relebactam against a Spanish nationwide collection of carbapenemase-producing Enterobacterales JC Vázquez-Ucha, A Seoane-Estévez, BK Rodiño-Janeiro, ... Journal of Antimicrobial Chemotherapy 76 (6), 1498-1510, 2021 | 31 | 2021 |
| Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection J Arca-Suárez, JC Vázquez-Ucha, PA Fraile-Ribot, E Lence, G Cabot, ... Journal of Antimicrobial Chemotherapy 75 (11), 3209-3217, 2020 | 31 | 2020 |
| Selection of AmpC β-lactamase variants and metallo-β-lactamases leading to ceftolozane/tazobactam and ceftazidime/avibactam resistance during treatment of MDR/XDR Pseudomonas … A Ruedas-López, I Alonso-García, C Lasarte-Monterrubio, ... Antimicrobial Agents and Chemotherapy 66 (2), e02067-21, 2022 | 30 | 2022 |
| Assessment of activity and resistance mechanisms to cefepime in combination with the novel β-lactamase inhibitors zidebactam, taniborbactam, and enmetazobactam against a … JC Vázquez-Ucha, C Lasarte-Monterrubio, P Guijarro-Sánchez, M Oviaño, ... Antimicrobial Agents and Chemotherapy 66 (2), e01676-21, 2022 | 28 | 2022 |
| In Vitro and In Vivo Assessment of the Efficacy of Bromoageliferin, an Alkaloid Isolated from the Sponge Agelas dilatata, against Pseudomonas aeruginosa D Pech-Puch, M Pérez-Povedano, M Martinez-Guitian, ... Marine Drugs 18 (6), 326, 2020 | 27 | 2020 |
| Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam-and ceftazidime/avibactam-resistant Pseudomonas … C Lasarte-Monterrubio, PA Fraile-Ribot, JC Vázquez-Ucha, G Cabot, ... Journal of Antimicrobial Chemotherapy 77 (10), 2809-2815, 2022 | 21 | 2022 |
| Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella … JC Vázquez-Ucha, M Martínez-Guitián, C Lasarte-Monterrubio, ... Biomedicine & Pharmacotherapy 130, 110606, 2020 | 17 | 2020 |
| Involvement of HisF in the Persistence of Acinetobacter baumannii During a Pneumonia Infection M Martínez-Guitián, JC Vázquez-Ucha, L Álvarez-Fraga, K Conde-Pérez, ... Frontiers in Cellular and Infection Microbiology 9, 310, 2019 | 13 | 2019 |
| Marine organisms from the Yucatan Peninsula (Mexico) as a potential natural source of antibacterial compounds D Pech-Puch, M Pérez-Povedano, P Gómez, M Martínez-Guitián, ... Marine Drugs 18 (7), 369, 2020 | 12 | 2020 |
| 6-Halopyridylmethylidene Penicillin-Based Sulfones Efficiently Inactivate the Natural Resistance of Pseudomonas aeruginosa to β-Lactam Antibiotics JC Vazquez-Ucha, D Rodriguez, C Lasarte-Monterrubio, E Lence, ... Journal of Medicinal Chemistry 64 (9), 6310-6328, 2021 | 11 | 2021 |
| Activity of aztreonam in combination with novel β-lactamase inhibitors against metallo-β-lactamase-producing Enterobacterales from Spain JC Vázquez-Ucha, I Alonso-Garcia, P Guijarro-Sánchez, ... International Journal of Antimicrobial Agents 61 (4), 106738, 2023 | 7 | 2023 |
| Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR … I Alonso-García, JC Vázquez-Ucha, C Lasarte-Monterrubio, ... Journal of Antimicrobial Chemotherapy 78 (5), 1195-1200, 2023 | 5 | 2023 |
| Carbapenem Resistance in Acinetobacter nosocomialis and Acinetobacter junii Conferred by Acquisition of blaOXA-24/40 and Genetic Characterization of the … C Lasarte-Monterrubio, P Guijarro-Sánchez, A Bellés, JC Vázquez-Ucha, ... Microbiology Spectrum 10 (1), e02734-21, 2022 | 5 | 2022 |
| Antimicrobial activity of cefiderocol against the carbapenemase-producing enterobacter cloacae complex and characterization of reduced susceptibility associated with metallo-β … C Lasarte-Monterrubio, P Guijarro-Sánchez, JC Vázquez-Ucha, ... Antimicrobial agents and chemotherapy 67 (5), e01505-22, 2023 | 4 | 2023 |
| Antimicrobial Diterpene Alkaloids from an Agelas citrina Sponge Collected in the Yucatán Peninsula D Pech-Puch, AM Forero, JC Fuentes-Monteverde, ... Marine Drugs 20 (5), 298, 2022 | 4 | 2022 |
| Activity of Imipenem, Meropenem, Cefepime, and Sulbactam in Combination with the β-Lactamase Inhibitor LN-1-255 against Acinetobacter spp. C Lasarte-Monterrubio, JC Vazquez-Ucha, M Maneiro, J Arca-Suarez, ... Antibiotics 10 (2), 210, 2021 | 4 | 2021 |
| In vitro development of imipenem/relebactam resistance in KPC-producing Klebsiella pneumoniae involves multiple mutations including OmpK36 disruption and KPC modification E Gato, P Guijarro-Sánchez, I Alonso-García, R Pedraza-Merino, A Conde, ... International Journal of Antimicrobial Agents 62 (4), 106935, 2023 | 3 | 2023 |
| Interplay between OXA-10 β-Lactamase Production and Low Outer-Membrane Permeability in Carbapenem Resistance in Enterobacterales I Alonso-García, JC Vázquez-Ucha, M Martínez-Guitián, ... Antibiotics 12 (6), 999, 2023 | 2 | 2023 |
| Reply to Shapiro, “Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales” JC Vázquez-Ucha, C Lasarte-Monterrubio, P Guijarro-Sánchez, M Oviaño, ... Antimicrobial Agents and Chemotherapy 66 (5), e00353-22, 2022 | 1 | 2022 |
Alejandro BeceiroINIBIC-SERGASDirección de correo verificada de sergas.es
